comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 17:19:31 - browse：7146

Ron Wyden (left), Mike Crapo (right) -- health policy coverage from STAT — Draft legislation authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers. Pete Marovich-Pool/Getty Images

WASHINGTON — A key Senate health care panel has developed a plan to tackle reforms to middlemen in the pharmacy drug payment system, according to bill text obtained by STAT.

The draft legislation, authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho), includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers.

The most significant measure is a bill from Sens. Bob Menendez (D-N.J.) and Marsha Blackburn (R-Tenn.) that would prohibit PBMs from getting any income outside of service fees, and prohibits those service fees from being related to drugs’ list prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： New weight loss drugs work. But how can they best be used?

WSS

3 medical device trends to watch in 2024

Why psychiatrists like me stop taking insurance

3 medical device trends to watch in 2024

3 medical device trends to watch in 2024

3 trends to watch in health tech's hiring outlook for 2024

The drug industry has found itself all alone in Washington

entertainment

comprehensive

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Feng Zhang, Grail founder join forces on new gene editing startup

Tori Bowie and the unacceptable rates of Black maternal death

The FDA must approve intranasal treatments for anaphylaxis

Jerome Adams on the need for new antivirals for Covid

A deep dive into Applied Therapeutics’ data, and questions on Cassava

FDA approval of Sarepta Duchenne genetic therapy gives me hope

3 medical device trends to watch in 2024

Sports medicine is finally prioritizing gender equality

Federal weight loss drug coverage is 30 years out of date

hotspot

Change Healthcare payments predicted restored March 15

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Novo Nordisk obesity pill bests Wegovy in early trial

The problem with charging patients to message their doctors

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

hotspot

focus

leisure time

hotspot